Delisting risk
Lunai Bioworks (LNAI)
Biomedical-AI analytics and zebrafish screening for preclinical discovery.
$2.33
Pre-market−0.10 (−4.12%)
At close$2.43(+13.02%)
In millions of USD, except per-share figures
| In millions | Q2 FY23Dec 2023 | Q3 FY23Mar 2024 | Q4 FY23Jun 2024 | Q1 FY24Sep 2024 | Q2 FY24Dec 2024 | Q3 FY24Mar 2025 | Q4 FY24Jun 2025 | Q1 FY25Sep 2025 | Q2 FY25Dec 2025 | Q3 FY25Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 9 | 51 | 53 | 5 | 4 | 4 | 2 | 2 | 1 | |
| Research & development | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 8 | 5 | 5 | 4 | 4 | 4 | 2 | 2 | 1 | |
| General & administrative | 0 | 0 | 5 | 5 | 4 | 4 | 4 | 2 | 0 | 0 |
| Other expenses | 0 | 0 | 46 | 48 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −4 | −9 | −51 | −53 | −5 | −4 | −4 | −2 | −2 | −1 |
| 0 | −50 | 1 | 9 | −3 | 4 | −123 | 5 | 0 | −1 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 50 | −3 | −9 | 3 | −5 | 122 | −5 | 0 | 1 |
| Income before tax | −5 | −59 | −50 | −44 | −7 | 0 | −127 | 3 | −2 | −3 |
| Net income from continuing operations | −5 | −59 | −50 | −44 | −7 | 0 | −127 | 3 | −2 | −3 |
| Net income | −5 | −59 | −50 | −44 | −7 | 0 | −127 | 3 | −2 | −3 |
| EPS, basic | −$5.52 | −$43.20 | −$31.04 | −$22.40 | −$3.20 | $0.09 | −$60.88 | $1.04 | −$0.61 | −$0.80 |
| EPS, diluted | −$5.52 | −$43.20 | −$31.04 | −$22.40 | −$3.20 | $0.09 | −$60.88 | $1.04 | −$0.61 | −$0.80 |
| Weighted average shares, basic | 1 | 1 | — | — | 2 | — | — | — | — | 3 |
| Weighted average shares, diluted | 1 | 1 | — | — | 2 | — | — | — | — | 3 |
| EBITDA | −4 | −59 | −48 | −44 | −7 | 0 | −127 | 3 | −2 | −2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −4 | −59 | −48 | −44 | −7 | 0 | −127 | 3 | −2 | −2 |
